Unicycive Therapeutics (UNCY) to Announce Earnings on Thursday

Unicycive Therapeutics (NASDAQ:UNCY) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Unicycive Therapeutics to post earnings of ($0.4710) per share and revenue of $22.2220 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 9:30 AM ET.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.08). On average, analysts expect Unicycive Therapeutics to post $-1 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Unicycive Therapeutics Stock Performance

Shares of UNCY opened at $5.02 on Tuesday. Unicycive Therapeutics has a 1 year low of $3.71 and a 1 year high of $8.74. The firm has a fifty day moving average of $6.09 and a 200-day moving average of $6.68. The company has a market cap of $137.50 million, a price-to-earnings ratio of -2.27 and a beta of 1.79.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vivo Capital LLC increased its stake in shares of Unicycive Therapeutics by 57.4% during the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock valued at $7,804,000 after acquiring an additional 652,901 shares during the period. Millennium Management LLC acquired a new stake in Unicycive Therapeutics in the fourth quarter worth approximately $5,856,000. Vanguard Group Inc. boosted its stake in Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after purchasing an additional 52,925 shares in the last quarter. Cantor Fitzgerald L. P. bought a new position in Unicycive Therapeutics during the 4th quarter valued at $1,154,000. Finally, Geode Capital Management LLC boosted its stake in Unicycive Therapeutics by 36.2% during the 4th quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock valued at $989,000 after purchasing an additional 45,563 shares in the last quarter. 40.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on UNCY shares. Weiss Ratings upgraded shares of Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 9th. HC Wainwright cut their price target on Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. B. Riley Financial reiterated a “buy” rating and set a $22.00 price objective on shares of Unicycive Therapeutics in a research report on Tuesday, June 30th. Guggenheim reissued a “buy” rating and issued a $37.00 price objective (down from $40.00) on shares of Unicycive Therapeutics in a report on Wednesday, May 13th. Finally, Benchmark lowered their target price on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating on the stock in a research report on Wednesday, July 1st. Five equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Unicycive Therapeutics currently has an average rating of “Hold” and an average target price of $21.75.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.